GenMont BiotechTPE:3164 +0.30%82 Current Ratio is 4.28 as of Dec. 2025, which is 1% above its 10-year median of 4.23. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$26.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,408 Biotechnology companies, GenMont Biotech ranks better than 52.7% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. GenMont Biotech's current ratio for the quarter that ended in Dec. 2025 was 4.28.
GenMont Biotech has a current ratio of 4.28. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for GenMont Biotech's Current Ratio or its related term are showing as below:
TPE:3164'
s Current Ratio Range Over the Past 10 Years
Min: 3.18 Med: 4.23 Max: 12.14
Current: 4.28
During the past 13 years, GenMont Biotech's highest Current Ratio was 12.14. The lowest was 3.18. And the median was 4.23.
TPE:3164's Current Ratio is ranked better than 52.7% of 1408
companies
in the Biotechnology industry
Industry Median: 3.9
vs TPE:3164: 4.28
GenMont Biotech (TPE:3164) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
GenMont Biotech Current Ratio Related Terms
GenMont Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for GenMont Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:3164 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, GenMont Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenMont Biotech Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenMont Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where GenMont Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenMont Biotech (TPE:3164) has a Current Ratio of 4.28 as of Dec. 2025. This is near median its historical median of 4.23. Over the past decade, GenMont Biotech's Current Ratio has ranged from 3.18 to 12.14. According to the industry distribution chart, GenMont Biotech ranks #666 out of 1408 companies in the Biotechnology industry, placing it in the top 47.3%.
Is GenMont Biotech's Current Ratio too high?
GenMont Biotech's current Current Ratio of 4.28 is near median its 10-year median of 4.23. Over the past 10 years, this metric has ranged from a low of 3.18 to a high of 12.14. The Biotechnology industry median Current Ratio is 3.90. GenMont Biotech's value of 4.28 is 9.7% above this industry median. Based on the distribution chart, GenMont Biotech ranks #666 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenMont Biotech ranks #666 out of 1408 companies for Current Ratio. This puts GenMont Biotech in the upper half of its industry. The industry median Current Ratio is 3.90. GenMont Biotech's value of 4.28 is 9.7% above this benchmark. Historically, GenMont Biotech's own Current Ratio has ranged from 3.18 to 12.14 over the past decade. While the company's 10-year median is 4.23 vs. the industry median of 3.90, GenMont Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GenMont Biotech's current Current Ratio of 4.28 is 9.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GenMont Biotech's current Current Ratio is 4.28, which is near median its own 10-year median of 4.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.24, compared to a current price of NT$16.55 — trading 36.9% below its estimated fair value. The current Current Ratio is 4.28, which is near median its 10-year median of 4.23 and 9.7% above the Biotechnology industry median of 3.90. GenMont Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current Current Ratio is 4.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GenMont Biotech (TPE:3164) Overvalued in 2026?
Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued.
The current stock price of NT$16.55 is trading 36.9% below its estimated GF Value™ of NT$26.24.
GuruFocus considers GenMont Biotech to be Significantly Undervalued.
Key valuation signals for TPE:3164:
Current Ratio: 4.28 (near median its 10-year median of 4.23)
GF Value™: NT$26.24 vs. price of NT$16.55 (36.9% below fair value)
Industry Position: 9.7% above the Biotechnology median (#666 of 1408)
No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score
Get the complete analysis for TPE:3164
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3164 has been successfully added to your 
